304693-70-7 Usage
Uses
Used in Organic Synthesis:
1H-Pyrazole-4-carboxaldehyde, 1-(2-methoxyethyl)(9CI) is used as a building block in organic synthesis for the creation of various pharmaceuticals and biologically active molecules. Its carboxaldehyde group allows for the formation of new chemical bonds, facilitating the synthesis of complex organic compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1H-Pyrazole-4-carboxaldehyde, 1-(2-methoxyethyl)(9CI) is utilized as a key intermediate in the development of new drugs. Its pyrazole core and 2-methoxyethyl substituent provide opportunities for structural modifications, potentially enhancing the pharmacological properties of the resulting compounds.
Used in Drug Development:
1H-Pyrazole-4-carboxaldehyde, 1-(2-methoxyethyl)(9CI) holds promise in drug development due to its potential biological activities and pharmacological properties. Further studies are required to fully understand its therapeutic potential and explore its applications in treating various diseases and conditions.
Used in Research:
As a subject of interest for research, 1H-Pyrazole-4-carboxaldehyde, 1-(2-methoxyethyl)(9CI) aids scientists in investigating its chemical properties, reactivity, and interactions with biological systems. This knowledge can contribute to the advancement of chemical and pharmaceutical sciences, leading to the discovery of novel therapeutic agents and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 304693-70-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,4,6,9 and 3 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 304693-70:
(8*3)+(7*0)+(6*4)+(5*6)+(4*9)+(3*3)+(2*7)+(1*0)=137
137 % 10 = 7
So 304693-70-7 is a valid CAS Registry Number.
304693-70-7Relevant academic research and scientific papers
FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION
-
Page/Page column 68, (2018/04/13)
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION
-
Page/Page column 72; 73, (2018/04/13)
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplasia syndrome (MDS) and diabetes.
2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS
-
Page/Page column 62, (2009/01/20)
The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently C(H)= or N=, provided that at least one of A and B is -N=, n is 1-3, m is 0-3, and R14 are as defined herein.
Pyrimidinone compounds
-
Page/Page column 24, (2008/06/13)
Pyrimidinone compounds of formula (I) are inhibitors of the enzyme Lp-PLA2 and of use in therapy, in particular for treating atherosclerosis.
